Kymera Therapeutics (KYMR) director awarded 6,068 stock options at $99.87

Rhea-AI Filing Summary

Kymera Therapeutics director Gorjan Hrustanovic reported receiving a grant of stock options covering 6,068 shares of Common Stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.

The underlying 6,068 shares vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. According to the disclosure, Hrustanovic is a member of BVF Partners L.P. and is obligated to transfer any economic benefit from the sale of shares issued upon exercise of these grants to BVF, and he disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hrustanovic Gorjan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 shares (Direct, null)

Footnotes (1)

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Key Figures

Option grant size: 6,068 shares Exercise price: $99.87 per share Expiration date: June 23, 2036 +2 more

5 metrics

Option grant size 6,068 shares Stock Option (Right to Buy) granted to director

Exercise price $99.87 per share Conversion or exercise price of stock option

Expiration date June 23, 2036 Option expiration for 6,068-share grant

Underlying shares 6,068 shares Common Stock issuable upon exercise of options

Post-grant derivative holdings 6,068 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), vest in full, beneficial ownership, pecuniary interest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vest in full financial

"The shares underlying this stock option shall vest in full upon the earlier"

beneficial ownership financial

"the Reporting Person disclaims beneficial ownership of the securities reported herein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:00 PM Accepted by SEC EDGAR 06/25/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hrustanovic Gorjan

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D(2)

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

2. The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kymera Therapeutics (KYMR) director Gorjan Hrustanovic receive in this Form 4?

Hrustanovic received a grant of stock options for 6,068 Kymera shares. The options are rights to buy Common Stock at a fixed exercise price and represent compensation rather than an open-market purchase or sale of existing shares.

What is the exercise price and term of the Kymera (KYMR) stock options granted?

The stock options have an exercise price of $99.87 per share and expire June 23, 2036. This means Hrustanovic can buy up to 6,068 shares at $99.87 any time before the expiration date, once the options vest.

When do the 6,068 Kymera (KYMR) option shares granted to Hrustanovic vest?

The 6,068 underlying shares vest in full on the earlier of June 24, 2027 or the next annual stockholder meeting. Vesting must occur before the options can be exercised to acquire Kymera common shares.

How is BVF Partners L.P. involved in this Kymera (KYMR) option grant?

Hrustanovic is a member of BVF Partners L.P. and must transfer any economic benefit from exercised shares to BVF. He therefore disclaims beneficial ownership of the reported securities except for any pecuniary interest he may have.

Does this Kymera (KYMR) Form 4 show an open-market buy or sell by the director?

No, the Form 4 reports a grant of stock options, not an open-market trade. The transaction is coded as a grant or award, categorized as an acquisition of derivative securities rather than a market purchase or sale of common stock.